PainReform Stock Price, News & Analysis (NASDAQ:PRFX) $2.74 +0.21 (+8.30%) (As of 02:20 PM ET) Add Compare Share Share Today's Range$2.54▼$2.8050-Day Range$1.85▼$3.6352-Week Range$1.82▼$26.41Volume29,301 shsAverage Volume376,036 shsMarket Capitalization$2.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media About PainReform Stock (NASDAQ:PRFX)PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 2007 and is based in Tel Aviv, Israel.Read More PRFX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRFX Stock News HeadlinesNovember 24, 2023 | americanbankingnews.comPainReform (NASDAQ:PRFX) Trading Up 4.4%November 19, 2023 | finanznachrichten.dePainReform Ltd: PainReform Provides Business Update for the Third Quarter of 2023December 4, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PainReform (PRFX) and Tenet Healthcare (THC)November 15, 2023 | finance.yahoo.comPainReform Provides Business Update for the Third Quarter of 2023November 12, 2023 | morningstar.comPainReform Ltd Ordinary Shares PRFXSeptember 12, 2023 | markets.businessinsider.comPainReform (PRFX) Gets a Buy from Maxim GroupSeptember 11, 2023 | finance.yahoo.comPainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master FileDecember 4, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.September 7, 2023 | finance.yahoo.comPainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySeptember 7, 2023 | finance.yahoo.comPainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySeptember 5, 2023 | finance.yahoo.comPainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York CityAugust 30, 2023 | finance.yahoo.comPRFX - PainReform Ltd.August 11, 2023 | finance.yahoo.comPainReform Provides Business Update for the Second Quarter of 2023July 19, 2023 | finanznachrichten.dePainReform Ltd: PainReform Regains Compliance with Nasdaq Continued Listing RequirementsJuly 19, 2023 | finance.yahoo.comPainReform Regains Compliance with Nasdaq Continued Listing RequirementsJuly 14, 2023 | markets.businessinsider.comPRFX Stock: The $2.7 Million Reason PainReform Is Up 100% TodayJuly 14, 2023 | finance.yahoo.comPainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private PlacementJuly 12, 2023 | marketwatch.comPainReform Shares Unwind From Tuesday Surge After PricingJuly 12, 2023 | msn.comPainReform (NASDAQ:PRFX) Tanks on $2.7M Registered Direct OfferingJuly 12, 2023 | finance.yahoo.comPainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private PlacementJuly 11, 2023 | benzinga.comWhat's Going On With PainReform (PRFX) Stock?July 11, 2023 | benzinga.comPainReform Shares Halted On Circuit Breaker To The Upside, Stock Now Up 125.4%July 7, 2023 | msn.comWhy Gorilla Technology Group Are Trading Higher By 52%; Here Are 20 Stocks Moving PremarketJune 15, 2023 | finance.yahoo.comPainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21stJune 10, 2023 | markets.businessinsider.comPainReform (PRFX) Receives a Buy from Maxim GroupJune 7, 2023 | benzinga.comPainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgerySee More Headlines Receive PRFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRFX CUSIPN/A CIK1801834 Webwww.painreform.com Phone972-3717-7051FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-77.50% Return on Assets-70.19% Debt Debt-to-Equity RatioN/A Current Ratio9.81 Quick Ratio8.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.92 per share Price / Book0.32Miscellaneous Outstanding Shares1,090,000Free Float715,000Market Cap$2.76 million OptionableNot Optionable Beta0.50 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Ehud Geller Ph.D.Executive ChairmanMr. Ilan Hadar M.B.A. (Age 54)CEO & CFO Comp: $457kDr. Sigal Aviel (Age 59)Chief Operating Officer Comp: $329kProf. Eli Hazum Ph.D.CTO & DirectorMs. Rita Keynan (Age 54)Vice President of Pharmaceutical Operations Comp: $315kDr. Stephen A. Cooper D.M.D Ph.D.Executive Vice President of DevelopmentMore ExecutivesKey CompetitorsZyVersa TherapeuticsNASDAQ:ZVSAScopus BioPharmaNASDAQ:SCPSAvenue TherapeuticsNASDAQ:ATXIAllarity TherapeuticsNASDAQ:ALLR180 Life SciencesNASDAQ:ATNFView All Competitors PRFX Stock Analysis - Frequently Asked Questions How have PRFX shares performed in 2023? PainReform's stock was trading at $4.1270 on January 1st, 2023. Since then, PRFX stock has decreased by 33.6% and is now trading at $2.74. View the best growth stocks for 2023 here. Are investors shorting PainReform? PainReform saw a decrease in short interest in November. As of November 15th, there was short interest totaling 400 shares, a decrease of 84.0% from the October 31st total of 2,500 shares. Based on an average daily volume of 19,200 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the company's shares are sold short. View PainReform's Short Interest. When is PainReform's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our PRFX earnings forecast. How were PainReform's earnings last quarter? PainReform Ltd. (NASDAQ:PRFX) issued its earnings results on Monday, November, 15th. The company reported ($1.80) EPS for the quarter, topping the consensus estimate of ($4.30) by $2.50. When did PainReform's stock split? PainReform's stock reverse split on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of PainReform own? Based on aggregate information from My MarketBeat watchlists, some companies that other PainReform investors own include Novartis (NVS), AbbVie (ABBV), American Airlines Group (AAL), Bank of America (BAC), Bristol-Myers Squibb (BMY), Clorox (CLX), Cisco Systems (CSCO), CVS Health (CVS), Delta Air Lines (DAL) and DocuSign (DOCU). When did PainReform IPO? (PRFX) raised $20 million in an initial public offering on Tuesday, September 1st 2020. The company issued 2,500,000 shares at a price of $8.00 per share. Maxim Group and Joseph Gunnar acted as the underwriters for the IPO. How do I buy shares of PainReform? Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:PRFX) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.